The European Commission has confirmed its original decision in 2014 to grant state aid approval for the Capacity Market, enabling it to be restored and payments that have been suspended since November 2018 to be made.

The Secretary of State for Business, Energy and Industrial Strategy has written to National Grid Electricity System Operator (ESO) and the Electricity Settlements Company (ESC) to notify them of the Commission’s decision and confirm that the trigger for the resumption of capacity payments has occurred.

These bodies are required to restart all Capacity Market functions that had been suspended during the standstill period.

Date: Wednesday 6 November 2019

Venue: San Siro Stadium, Milan, Italy

Kick off time: 9.00pm

As well as this advice, check out our travel advice for Italy

Passports and visas

• you don’t need a visa to travel to Italy, but your passport should be valid for the duration of your stay
• remember your European Health Insurance Card (EHIC) but also take out travel insurance, even if you are only going for one night. It could save you a lot of money if you get into difficulties
• you must carry ID with you at all times – you’ll need to carry your passport to the match to gain entry to the stadium
• if you lose your passport, you’ll need to get an Emergency Travel Document from the British Consulate in Milan

Getting to the stadium

• please remember to validate your tickets before travel
• the San Siro Stadium can be reached from the centre of Milan by Underground (e.g., from Duomo get the Red Line M1 West – change at Lotto – get the Lilac line M5 getting off at San Siro Stadio)
• the journey time is around 30 minutes. A single ticket for the underground costs €2 and is valid for one journey. Tickets can be purchased from machines or newsstands at all underground stops
• tram no.16 also runs regularly from Duomo to the stadium. A single ticket for the tram costs €2 and is valid for 90 minutes from the first validation on all above-ground buses and trams

Local information and transport

At the match

• you should arrive at the stadium in good time as entry/security procedures may take some time to complete
• large amounts of coins, belts with large buckles and heavy cigarette lighters aren’t allowed in the stadium; check with Manchester City FC if you need more information about the stadium rules, forbidden items and rules on banners/flags
• at the end of the game, you’ll be asked to stay in the stadium for a short time to allow the home supporters’ area to be cleared
• the Italian government has a zero tolerance policy on hooliganism both inside and outside the stadium

Tips

• as in any other city beware of pickpockets and bag snatchers at airports, railway stations, around the town centre and when using public transport – only carry what you need and leave spare cash and valuables in hotel safety deposits
• if you’re travelling in a car, remember to always lock the vehicle and never leave valuables inside; hire cars and foreign registered vehicles are more of a target for thieves

Contact the British Consulate in Milan

Tel. +39 02 72 3001

For further information, please visit the British Consulate Milan website or UKinItaly Facebook

Emergency services numbers

• police (Carabinieri): 112
• ambulance: 118
• fire brigade: 115

Further information

This is the eleventh edition of the serious and organised crime (SOC) local partnerships bulletin for August 2019.

The SOC partnerships bulletin is released on a quarterly basis by the Home Office’s SOC policy group. If you have an article which you would like to feature in a future edition, or any feedback, suggestions or questions, please email SCOC.localpartnerships@homeoffice.gov.uk

Around 200 people packed into a venue in Wick, Caithness to hear about plans for future work to decommission the site. Firms of all sizes from the local area and beyond represented a number of industries ranging from engineering, construction and demolition firms to support services.

Jane Mackenzie, Head of Commercial Services, said:

Earlier this year we awarded framework contracts and, in partnership with the successful organisations, we wanted to talk to the wider supply chain about the opportunities that will now exist to support and assist them deliver their commitments. The decommissioning of Dounreay is a complex programme and no single company has all the right skills and capabilities, so that enables others to play their part and help us deliver our mission.

The framework contracts, potentially worth up to £400 million, are due to last up to 4 years with the possibility of extensions of up to an additional 3 years. Lead organisations appointed included AECOM E&C UK, Dounreay Decommissioning Framework Alliance, Dounreay Wood Alliance, Jacobs UK, Nuclear Decommissioning Ltd and Nuvia.

The first contract to be awarded under the framework arrangement is due to be announced later in the year, supporting preparations to decommission the site’s shaft and silo facilities.

Watch highlights from the event:

Supply chain day September 2019

Once the UK’s centre of fast reactor research, Dounreay is now aiming to be recognised globally for decommissioning excellence. The work is being delivered on behalf of the Nuclear Decommissioning Authority by Dounreay Site Restoration Limited, a company owned by Cavendish Dounreay Partnership.

An alert has been issued to healthcare professionals to recall 1 prescription-only product; Ranitidine 150mg/10ml Oral Solution produced by the company.

A second alert has been issued for medicines available both and over-the-counter and on general sale under the branding of Zantac, Galpharm, Boots, Kirkland, and Morrisons. A full list of all the products and batches affected can be found in the MHRA drug alert here.

In both alerts, healthcare professionals and retailers have been told to stop supplying the products immediately. All remaining stock should be quarantined and returned without delay to the supplier. Patients should not stop taking their medication, and a treatment review is not necessary until the next routine appointment.

The Perrigo recall is a precautionary measure due to possible contamination of the active substance in Zantac, ranitidine, with an impurity called NDMA (N-nitrosodimethylamine) which has been identified as a risk factor in the development of certain cancers.

The MHRA is actively involved with the European Medicines Agency and other medicines’ regulators to determine the impact of what is an ongoing, global issue. On 8 October and 17 October, MHRA drug alerts were also issued regarding the withdrawal of other, prescription-only ranitidine medicines.

An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses. Other Ranitidine products have been quarantined, and the Department of Health and Social Care issued an alert on 15 October regarding shortages of the medicine and advice to healthcare professionals on alternative treatments. The DHSC has also added Ranitidine to a list of medicines subject to export restrictions.

Dr Andrew Gray, MHRA Deputy Director of Inspections, Enforcement & Standards, comments:

“Whilst this action is precautionary, the MHRA takes patient safety very seriously.

“Patients should keep taking their current medicines but should speak to their doctor or pharmacist if they are concerned and should seek their doctor’s advice before stopping any prescribed medicines.

“We have asked companies to quarantine batches of potentially affected medicines whilst we investigate and we will take action as necessary, including product recalls where appropriate.

“We have also requested risk assessments from the relevant companies which will include the testing of potentially affected batches.

“Currently, there is no evidence that medicines containing nitrosamines have caused any harm to patients, but the Agency is closely monitoring the situation, and working with other Regulatory Agencies around the world.”

Note to editors:

1. Medicines and Healthcare products Regulatory Agency is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.

2. MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes the National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD). MHRA is an executive agency of the Department of Health and Social Care.